WO2022121864A1 - Marker combination for skin typing and use thereof - Google Patents
Marker combination for skin typing and use thereof Download PDFInfo
- Publication number
- WO2022121864A1 WO2022121864A1 PCT/CN2021/135870 CN2021135870W WO2022121864A1 WO 2022121864 A1 WO2022121864 A1 WO 2022121864A1 CN 2021135870 W CN2021135870 W CN 2021135870W WO 2022121864 A1 WO2022121864 A1 WO 2022121864A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- moraxella
- oslo
- acnes
- level
- Prior art date
Links
- 239000003550 marker Substances 0.000 title claims abstract description 38
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 94
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 34
- 229940055019 propionibacterium acne Drugs 0.000 claims abstract description 30
- 241000588621 Moraxella Species 0.000 claims description 100
- 230000036555 skin type Effects 0.000 claims description 70
- 241000894006 Bacteria Species 0.000 claims description 42
- 230000009759 skin aging Effects 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 38
- 230000037394 skin elasticity Effects 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 24
- 230000003247 decreasing effect Effects 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 14
- 239000004615 ingredient Substances 0.000 claims description 13
- 238000012216 screening Methods 0.000 claims description 13
- 238000012163 sequencing technique Methods 0.000 claims description 11
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 10
- 206010000496 acne Diseases 0.000 claims description 10
- 241000191940 Staphylococcus Species 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 6
- 241001464975 Cutibacterium granulosum Species 0.000 claims description 4
- 241000542065 Moraxella bovoculi Species 0.000 claims description 4
- 241000557299 Psychrobacter sp. Species 0.000 claims description 4
- 230000003712 anti-aging effect Effects 0.000 claims description 4
- 238000004364 calculation method Methods 0.000 claims description 4
- 241001464974 Cutibacterium avidum Species 0.000 claims description 3
- 238000012512 characterization method Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 229940055009 propionibacterium avidum Drugs 0.000 claims description 3
- 238000002331 protein detection Methods 0.000 claims description 3
- 241000186429 Propionibacterium Species 0.000 claims description 2
- 241001478294 Moraxella osloensis Species 0.000 abstract description 10
- 210000003491 skin Anatomy 0.000 description 211
- 239000000523 sample Substances 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 244000005700 microbiome Species 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 24
- 239000002609 medium Substances 0.000 description 20
- 230000001580 bacterial effect Effects 0.000 description 19
- 210000001061 forehead Anatomy 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 150000004032 porphyrins Chemical class 0.000 description 14
- 244000005714 skin microbiome Species 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 238000011529 RT qPCR Methods 0.000 description 13
- 241000191963 Staphylococcus epidermidis Species 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000002596 correlated effect Effects 0.000 description 12
- 230000000813 microbial effect Effects 0.000 description 12
- 239000011148 porous material Substances 0.000 description 12
- 238000010219 correlation analysis Methods 0.000 description 10
- 230000032683 aging Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 241000894007 species Species 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000003559 RNA-seq method Methods 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 210000002374 sebum Anatomy 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 230000019612 pigmentation Effects 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 4
- 235000013734 beta-carotene Nutrition 0.000 description 4
- 239000011648 beta-carotene Substances 0.000 description 4
- 229960002747 betacarotene Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000036559 skin health Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000036572 transepidermal water loss Effects 0.000 description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 101100242035 Bacillus subtilis (strain 168) pdhA gene Proteins 0.000 description 2
- 101100350224 Bacillus subtilis (strain 168) pdhB gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101100236536 Corynebacterium glutamicum (strain ATCC 13032 / DSM 20300 / BCRC 11384 / JCM 1318 / LMG 3730 / NCIMB 10025) glcB gene Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 101100123255 Komagataeibacter xylinus aceC gene Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 101100134871 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) aceE gene Proteins 0.000 description 2
- 101100406344 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) aceF gene Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 101150094017 aceA gene Proteins 0.000 description 2
- 101150036393 aceB gene Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 101150070136 axeA gene Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010201 enrichment analysis Methods 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- -1 inositol Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- DYNFCHNNOHNJFG-UHFFFAOYSA-N 2-formylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C=O DYNFCHNNOHNJFG-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102100034229 Citramalyl-CoA lyase, mitochondrial Human genes 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 1
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 108020004687 Malate Synthase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700005443 Microbial Genes Proteins 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 230000007691 collagen metabolic process Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 231100000507 endocrine disrupting Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 244000005702 human microbiome Species 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000005900 regulation of collagen biosynthetic process Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/44—Staphylococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/21—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pseudomonadaceae (F)
- G01N2333/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella or Psychrobacter
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
- G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
Definitions
- the present invention relates to the field of biomedicine, in particular to a marker combination for skin typing and its application.
- the purpose of the present invention is to classify the population based on the characteristics of the skin microbiome, thereby helping the industry to develop skin care products and medicines that are more suitable for specific populations for different skin types.
- the present invention will focus on the two bacteria that dominate skin typing, Moraxella osloensis and Cutibacterium acnes, as well as skin-abundant bacteria that play an important role in host health and disease. on one of the bacterial colonies of the species, Staphylococcus epidermidis.
- the correlation between the distribution abundance of three target skin symbionts on the face and the host skin phenotype was determined. The bacteria that promote skin aging - M. osloensis.
- M. osloensis or a detection reagent thereof for (a) skin typing; and/or (b) judging or characterizing skin conditions or using For preparing a reagent or kit for (a) skin typing; and/or (b) determining or characterizing skin condition.
- the skin condition includes: skin age, skin moisture content, skin elasticity, skin color, and skin aging degree.
- the aging degree of the skin is judged based on one or more phenotypes selected from the group consisting of porphyrin, oil, water content, gloss, pore area, skin yellowness, pore size, and pigmentation.
- the reagent or kit further includes a reagent for detecting Propionibacterium acnes (C. acnes).
- the reagent or kit further includes a reagent for detecting Moraxella bovoculi and/or Psychrobacter sp.
- the reagent or kit further comprises detection of Propionibacterium avidum, Propionibacterium granulosum, Staphylococcus, Propionibacterium acnes and/or Staphylococcus phage reagent.
- the reagent or kit further includes a reagent for detecting Staphylococcus epidermidis (S. epidermidis).
- a second aspect of the present invention provides a marker combination comprising M. osloensis and C. acnes.
- the marker combination further includes Moraxella bovoculi and/or Psychrobacter sp..
- the marker combination further includes Propionibacterium avidum, Propionibacterium granulosum, Staphylococcus, Propionibacterium acnes and/or Staphylococcus phage.
- the marker combination further includes Staphylococcus epidermidis (S. epidermidis).
- the marker combination is used for (a) skin typing; and/or (b) judging skin state.
- the skin condition includes: skin age, skin moisture content, skin elasticity, skin color, and skin aging degree.
- the aging degree of the skin is judged based on one or more phenotypes selected from the group consisting of porphyrin, oil, water content, gloss, pore area, skin yellowness, pore size, and pigmentation.
- the marker or marker combination is derived from a skin sample, preferably from whole body skin or facial skin, more preferably from cheek, forehead, and nose.
- the marker or marker combination is derived from skin samples of Asian population.
- the marker or marker combination is derived from cheek, forehead, and alar samples.
- the level of each marker in the marker combination is detected by one or more methods of the following group: sequencing, PCR, protein quantitative detection.
- the method for detecting the level of the marker group further includes one or more methods selected from the group consisting of: quantitative PCR for characteristic genes, qPCR, real-time quantitative PCR, metagenomics analysis, 16s RNA sequencing , mass spectrometry, and western blotting.
- the ratio (M/ C) When the following conditions are met: M/C ⁇ 1.3, preferably, M/C ⁇ 0.8, more preferably M/C ⁇ 0.4, then the skin type is type C (or type I), and its phenotype includes: oil High content, high water content, good skin elasticity, low skin aging, bright skin color.
- the ratio (M/ C) When the following conditions are met: 0.3 ⁇ M/C ⁇ 2.5, preferably, 0.3 ⁇ M/C ⁇ 2.3, more preferably, 0.8 ⁇ M/C ⁇ 1.8, then the skin type is mixed (or type II) , and its phenotypes include: medium oil content, medium water content, average skin elasticity, moderate skin aging, and medium skin color.
- the ratio (M/ C) When the following conditions are met: M/C ⁇ 0.5, preferably, M/C ⁇ 1.8, more preferably, M/C ⁇ 2.2, then the skin type is M type (type III), and its phenotype includes skin oil Low content, low water content, poor skin elasticity, high degree of skin aging, dull skin color.
- the ratio (M/ C) When the following conditions are met: M/C ⁇ 1.5, preferably, M/C ⁇ 1.25, the skin type is type C (or type I), and its phenotype includes high oil content, high water content, and good skin elasticity , Low degree of skin aging, bright skin color.
- the ratio (M/ C) When the following conditions are met: M/C ⁇ 0.5, preferably, M/C ⁇ 0.35, the skin type is type C (or type I), and its phenotype includes high oil content, high water content, good skin elasticity, Low level of skin aging, bright skin color.
- the ratio (M/C) of the level (such as content) (M) of the Moraxella oslo to the level (such as content) (C) of the P. acnes is derived from a sample from the nose wing ) when the following conditions are met: 0.35 ⁇ M/C ⁇ 0.7, preferably, 0.35 ⁇ M/C ⁇ 0.6, more preferably, 0.35 ⁇ M/C ⁇ 0.55, the skin type is mixed type (or type II), which Phenotypes include: moderate oil content, moderate moisture content, moderate skin elasticity, moderate skin aging, and moderate skin color.
- the ratio (M/C) of the level (such as content) (M) of the Moraxella oslo to the level (such as content) (C) of the P. acnes is derived from a sample from the nose wing ) when the following conditions are met: M/C ⁇ 0.5, preferably, M/C ⁇ 0.55, the skin type is M type (type III), and its phenotype includes low skin oil content, low water content, poor skin elasticity, High degree of skin aging, dull skin color.
- a third aspect of the present invention provides a method for skin typing or judging skin state, the method comprising:
- the subject to be tested is from an Asian population.
- step (2) according to the relative value (such as M/C) of the level (such as content) (M) of Moraxella oslo and the level (such as content) (C) of P. acnes Type the skin, or determine the skin condition of a sample.
- the skin condition includes skin age, skin moisture content, skin elasticity, skin color, and skin aging degree.
- the level (eg content) (M) of Moraxella oslo and the level (eg content) of P. acnes in the sample of the subject to be tested by one or more methods selected from the following group (C) Confirmation: sequencing, PCR, protein quantitative detection.
- the method for detecting the level (eg content) (M) of Moraxella oslo and the level (eg content) (C) of Propionibacterium acnes in the sample further comprises a method selected from the group consisting of: One or more methods: quantitative PCR for signature genes, qPCR, real-time quantitative PCR, metagenomics analysis, 16s RNA sequencing, mass spectrometry, Western blotting.
- the ratio (M/C) of the Moraxella oslo (M) to the level (such as content) (C) of the P. acnes in the sample meets the following conditions: M/C ⁇ 1.3, preferably, M/C ⁇ 0.8, more preferably M/C ⁇ 0.4, then the skin type is C type (or type I), and its phenotype includes: high oil content, high water content, Good skin elasticity, low skin aging, bright skin color.
- the ratio (M/C) of the level (eg content) (M) of the Moraxella oslo in the sample to the level (eg content) (C) of the P. acnes When the following conditions are met: 0.3 ⁇ M/C ⁇ 2.5, preferably, 0.3 ⁇ M/C ⁇ 2.3, more preferably, 0.8 ⁇ M/C ⁇ 1.8, then the skin type is mixed (or type II), and its Phenotypes include: moderate oil content, moderate moisture content, moderate skin elasticity, moderate skin aging, and moderate skin color.
- the ratio (M/C) of the level (eg content) (M) of the Moraxella oslo in the sample to the level (eg content) (C) of the P. acnes When the following conditions are met: M/C ⁇ 0.5, preferably, M/C ⁇ 1.8, more preferably, M/C ⁇ 2.2, the skin type is M type (type III), and its phenotype includes low skin oil content , low water content, poor skin elasticity, high degree of skin aging, dull skin color.
- the sample is derived from the cheek, and the ratio of the level (such as content) (M) of Moraxella oslo in the sample to the level (such as content) (C) of Propionibacterium acnes ( When M/C) meets the following conditions: M/C ⁇ 0.8, preferably, M/C ⁇ 0.75, then the skin type is C type (or type I), and its phenotype includes high oil content, high water content, skin Good elasticity, low skin aging, bright skin color.
- the sample is derived from the cheek, and the ratio of the level (such as content) (M) of Moraxella oslo in the sample to the level (such as content) (C) of Propionibacterium acnes ( When M/C) meets the following conditions: 0.75 ⁇ M/C ⁇ 2, preferably, 0.8 ⁇ M/C ⁇ 1.7, then the skin type is mixed type (or type II), and its phenotype includes: medium oil content, Moderate moisture content, average skin elasticity, moderate skin aging, and moderate skin tone.
- the sample is derived from the cheek, and the ratio of the level (such as content) (M) of Moraxella oslo in the sample to the level (such as content) (C) of Propionibacterium acnes ( When M/C) meets the following conditions: M/C ⁇ 1.7, the skin type is M type (type III), and its phenotypes include low skin oil content, low water content, poor skin elasticity, high skin aging, and skin Dull in color.
- M level of Moraxella oslo in the sample
- C content of Propionibacterium acnes
- the ratio of the level (eg content) (M) of Moraxella oslo in the sample to the level (eg content) (C) of Propionibacterium acnes (M/C)
- M/C the ratio of the level (eg content) (M) of Moraxella oslo in the sample to the level (eg content) (C) of Propionibacterium acnes
- the sample is derived from the forehead, the ratio of the level (eg content) (M) of Moraxella oslo in the sample to the level (eg content) (C) of Propionibacterium acnes ( M/C) when the following conditions are met: 1.25 ⁇ M/C ⁇ 2.5, preferably, 1.3 ⁇ M/C ⁇ 2.2, the skin type is mixed (or type II), and its phenotype includes: medium oil content, high The amount of water is medium, the skin elasticity is average, the skin aging is medium, and the skin color is medium.
- the sample is derived from the forehead, the ratio of the level (eg content) (M) of Moraxella oslo in the sample to the level (eg content) (C) of Propionibacterium acnes ( When M/C) meets the following conditions: M/C ⁇ 2, preferably ⁇ 2.2, the skin type is M type (type III), and its phenotype includes low skin oil content, low water content, and poor skin elasticity , High degree of skin aging, dull skin color.
- the ratio of the level (eg content) (M) of Moraxella oslo in the sample to the level (eg content) (C) of Propionibacterium acnes (M/C)
- M/C the ratio of the level (eg content) (M) of Moraxella oslo in the sample to the level (eg content) (C) of Propionibacterium acnes
- M/C is derived from a sample from the nose wing, and the ratio of the level (such as content) (M) of Moraxella oslo in the sample to the level (such as content) (C) of Propionibacterium acnes (
- M/C meets the following conditions: 0.35 ⁇ M/C ⁇ 0.7, preferably, 0.35 ⁇ M/C ⁇ 0.6, more preferably, 0.35 ⁇ M/C ⁇ 0.55, the skin type is mixed (or type II) ), and their phenotypes include: medium oil content, medium water content, average skin elasticity, moderate skin aging, and medium skin color.
- it is derived from a sample from the nose wing, and the ratio of the level (such as content) (M) of Moraxella oslo in the sample to the level (such as content) (C) of Propionibacterium acnes ( M/C) when the following conditions are met: M/C ⁇ 0.5, preferably, M/C ⁇ 0.55, the skin type is M type (type III), and its phenotype includes low skin oil content, low water content, skin Poor elasticity, high degree of skin aging, dull skin color.
- the relative value meets the following conditions: when M/C ⁇ 1.3, the skin is type C, and when M/C ⁇ 0.5, the skin is type M.
- the relative value meets the following condition: when 0.3 ⁇ M/C ⁇ 2.5, the skin is of mixed type.
- the level (such as content) (M) of the Moraxella oslo increases, it indicates that the skin condition is increased skin age, dark and yellow complexion, reduced skin moisture content, sebum and porphyrin content reduce.
- the fourth aspect of the present invention provides a reagent combination for skin typing and/or skin condition detection, the reagent combination comprising reagents for detecting each marker in the combination described in the second aspect of the present invention.
- the reagent is used to detect the level (eg content) of each marker.
- the reagent includes a substance for detecting the level of each marker in the combination described in the second aspect of the present invention by one or more methods selected from the group consisting of sequencing, PCR, and quantitative protein detection.
- the method for detecting the marker level further includes: quantitative PCR of characteristic genes, qPCR, real-time quantitative PCR, metagenomic analysis, 16s RNA sequencing, mass spectrometry analysis, and western blotting.
- the reagent combination includes:
- a first detection reagent for detecting the level (M) of Moraxella oslo for detecting the level (M) of Moraxella oslo;
- a fifth aspect of the present invention provides a kit comprising the reagent combination described in the second aspect of the present invention.
- each marker in the combination described in the second aspect of the present invention is used as a standard.
- a sixth aspect of the present invention provides a system for classifying the skin of an object to be tested and/or judging the skin state of the object to be tested, the system comprising:
- a feature receiving module is used for receiving skin sample feature data;
- the feature data includes: the quantitative information of each of Moraxella oslo (M) and P. acnes (C) in the skin sample ;
- a calculation processing module for calculating the feature data from the feature receiving module, so as to obtain the respective proportions of the respective features or the proportional relationship between the respective features; and based on the obtained respective proportions or the relationship between the respective features A proportional relationship, compared with a standard value for skin type or characterization, resulting in a judgment of skin type and/or skin condition;
- the subject is a human.
- the subject is an Asian population.
- the objects include men and women.
- the subject includes infants, adolescents or adults.
- the quantitative information includes the respective levels (eg content) of Moraxella oslo (M) and Propionibacterium acnes (C).
- the proportional relationship includes the relative values of the respective levels (eg contents) of Moraxella oslo (M) and Propionibacterium acnes (C) in the skin sample, such as M/C.
- M Moraxella oslo
- C Propionibacterium acnes
- the system can be divided into at least two types according to the skin condition.
- the method for obtaining the quantitative information includes: sequencing, PCR, and quantitative protein detection.
- the method for obtaining the quantitative information further includes: quantitative PCR for characteristic genes, qPCR, real-time quantitative PCR, metagenomics analysis, 16s RNA sequencing, mass spectrometry analysis, and western blotting.
- the feature receiving module includes a sample collector and a feature signal input end.
- the calculation processing module includes a processor and a storage, wherein the storage stores threshold information of skin type and/or skin state.
- the output module includes any terminal, preferably a display, a printer, a tablet computer (PAD), and a smart phone.
- the modules are connected in a wired or wireless manner.
- a seventh aspect of the present invention provides a method for screening substances or ingredients for improving skin condition, comprising:
- the screening bacteria is Moraxella oslo (M), P. acnes (C), or screening bacteria (mixed bacteria) comprising Moraxella oslo and/or P. acnes;
- the content of Moraxella oslo or the relative level (such as relative content) (M/C) between Moraxella oslo and P. acnes increases, it indicates the substance to be screened Or the ingredients are substances used to treat acne.
- the level (such as content) of Moraxella oslo decreases or the relative level (such as relative content) (M/C) between Moraxella oslo and P. acnes decreases, it indicates that the The substances or ingredients to be screened are skin anti-aging substances.
- the level (such as content) of P. acnes increases or the relative level (such as relative content) (C/M) between P. acnes and Moraxella oslo increases, it indicates that the The substances or ingredients to be screened are skin anti-aging substances.
- the level (such as content) of P. acnes decreases or the relative level (such as relative content) (C/M) between P. acnes and Moraxella oslo decreases, it indicates that the The substance or ingredient to be screened is a substance for treating acne.
- the eighth aspect of the present invention provides a use of the marker combination according to the second aspect of the present invention or the reagent combination according to the fourth aspect of the present invention, for preparing a kit for use in (a) skin typing; and/or (b) judging or characterizing skin condition.
- the ninth aspect of the present invention provides the use of the combination of markers described in the second aspect of the present invention or the combination of reagents described in the fourth aspect of the present invention for screening substances or components that improve skin condition.
- Figure 1 shows a schematic diagram of the sampled skin site.
- Figure 2 shows the microbial composition of the facial skin of the Han population.
- Figure 3 shows the analysis of the optimal number of clusters for different parts.
- Figure 4A and B show the clustering results of the forehead, where the box plots represent the average distance between samples in the two groups, respectively, and the red line represents the average distance between samples in different groups.
- 4A is the JS divergence (Jensen-Shannon divergence)
- 4B is the Bray-Curtis dissimilarity (Bray-Curtis dissimilarity).
- Figure 4C,D show the relative levels of P. acnes or M. oslo on the forehead, with each dot representing a sample.
- Figure 4E and F show the clustering results of cheeks, where the box plots represent the average distance between samples in the two groups, respectively, and the red line represents the average distance between samples in different groups.
- 4E is JS divergence (Jensen-Shannon divergence)
- 4F is Bray-Curtis dissimilarity (Bray-Curtis dissimilarity).
- Figures 4G,H show relative levels of P. acnes or M. oslo in cheeks, with each dot representing a sample.
- Figure 4I and J show the clustering results of the nose ala, where the box plots represent the average distance between samples in the two groups, respectively, and the red line represents the average distance between samples in different groups.
- 4I is the JS divergence (Jensen-Shannon divergence)
- 4J is the Bray-Curtis dissimilarity (Bray-Curtis dissimilarity).
- Figure 4K,L show the relative levels of P. acnes or M. oslo in the nasal ala, with each dot representing a sample.
- Figure 5 shows the differential microorganisms between different skin types, with colors representing the relative levels of microorganisms, one sample per column and one microorganism per row.
- Figure 6 shows the microbial network characteristics of different skin types, with M-cutotype-enriched microbial species on the left and C-cutotype-enriched microbial species on the right. Each dot represents a species, and each color of the bouquet represents a species. It can be seen from the figure that the enriched microorganisms in one skin type are positively correlated with each other and negatively correlated with the enriched species of another skin type. Different skin types show different microbial network compositions.
- Figure 7 shows the differences in functional enrichment of skin microbial genes for different skin types.
- Figure 8 shows phenotypic differences between different skin types.
- Figure 9 shows the correlation analysis between Moraxella oslo and age and skin phenotype: adjusted P value is less than 0.05.
- Figure 10 shows that aceA/aceB genes are enriched in M-Cutotype.
- Figure 11 shows that the beta-Carotene synthesis pathway is enriched for M-Cutotype.
- Figure 12 shows the functional enrichment analysis of RNAseq differentially expressed genes in human keratinocyte HaCaT treated with Moraxella oslo supernatant and blank control group.
- Figure 13 shows the utilization of various water-soluble carbon source compounds by Moraxella oslo.
- the left picture is measured by CCK-8 kit, and the right picture is measured by Dye mix A.
- Figure 14 shows the results of skin type validation using Singapore Chinese skin metagenomic data.
- Figure 15 shows the results of skin type validation using Philippine and Italian skin metagenomic data.
- Figure 16 shows a heatmap of the correlation between species level and host phenotype of three dermatosymbionts.
- Figure 17 shows a graph of Moraxella oslo-HaCaT-QPCR results.
- Figure 18 shows a graph of P. acnes-HaCaT-QPCR results.
- Figure 19 shows a graph of S. epidermidis-HaCaT-QPCR results.
- Moraxella oslo can be used to characterize skin conditions or for skin typing for the first time, and the present invention also discovered a new marker combination for the first time: Moraxella oslo and C. acnes Acidobacter.
- the marker combination of the present invention can (a) classify the skin; and/or (b) judge the skin state, has the advantages of high sensitivity and high specificity, and has important application value. On this basis, the inventors have completed the present invention.
- the term "marker combination” refers to a combination of two or more markers.
- the level of the marker substance is determined by the ratio of the presence and/or expression of the two microorganisms.
- the term "individual” refers to animals, especially mammals, such as primates, preferably humans.
- the term “about” means that the value may vary by no more than 1% from the recited value.
- the expression “about 100” includes all values between 99 and 101 and (eg, 99.1, 99.2, 99.3, 99.4, etc.).
- the terms "containing” or “including (including)” can be open, semi-closed, and closed. In other words, the term also includes “consisting essentially of,” or “consisting of.”
- M bacteria Moraxella Osloensis, M.osloensis, hereinafter referred to as M bacteria
- Moraxella oslo Moraxella spp., bacilli, gram-negative, chemoorganotrophic bacteria. Can not use carbohydrates to produce acid.
- C bacteria Propionibacterium acnes, Cutibacterium acnes, C. acnes, hereinafter referred to as C bacteria
- Propionibacterium acnes a gram-positive bacillus, is a genus of Propionibacterium in the Actinomycete Actinomycete Actinomycetales. Important colonizer of human skin, involved in maintaining skin health, and can also act as a causative agent of acne vulgaris.
- Staphylococcus epidermidis Staphylococcus epidermidis, Staphylococcus epidermidis, S. epidermidis
- Staphylococcus epidermidis It is a gram-positive coccus that breeds on the epidermis of organisms. It exists in the skin, vagina and other parts of the human body. Because it often accumulates into grape clusters, it is named Staphylococcus epidermidis.
- the skin can be further classified into M-Cutotype type (referred to as M type), mixed type, and C-Cutotype type (referred to as C type).
- M type M-Cutotype
- C type C-Cutotype type
- C-Cutotype As used herein, the terms "C-Cutotype”, “C-type” are used interchangeably and refer to a type of microbe-based skin typing characterized by high levels of aggregation of P. acnes (C. acnes).
- M-Cutotype As used herein, the terms "M-Cutotype", “M-type” are used interchangeably and refer to a type of microbe-based skin typing characterized by high levels of aggregation of M. osloensis.
- skin elasticity depends on, but is not limited to, the adequacy of skin moisture, collagen, elastin, and natural fats, among others.
- skin color depends on, but is not limited to, skin radiance, skin tone, yellowness, and the like.
- skin aging depends on, but is not limited to, increased skin porphyrins, decreased skin moisture content and radiance, enlarged and enlarged pores, skin oil imbalance, and dull skin.
- M/C ratio can be obtained in the following ways: 1. 16sRNA sequencing; 2. Metagenome sequencing; 3. Characteristics of two species Sequence design primers, and then use qPCR to obtain the M/C ratio; 4. Detect the specific expressed proteins or metabolites of the two bacteria for quantitative purposes, such as mass spectrometry analysis, Western blotting, etc.
- the kit of the present invention includes the combination described in the second aspect of the present invention and/or the reagent combination described in the fourth aspect of the present invention.
- each marker in the combination described in the first aspect of the present invention is used as a standard.
- the present invention uses Moraxella oslo and Propionibacterium acnes as markers in combination for (a) skin typing; and/or (b) judging skin condition, such as moisture content, skin elasticity, and/or aging degree , has the advantages of high sensitivity and high specificity, and has important application value.
- the present invention discovers for the first time a new classification method that is different from the previous classification based on the host physiological drive (oily skin, dry skin, wet skin).
- the new classification method uses skin microorganisms as the classification basis.
- the microbiome communities of different skin types may react against the host skin by exerting specific functions, which may have certain effects on skin health and skin appearance. Therefore, further research on skin type may contribute to the development of personalized medicine to better maintain skin health.
- the present invention finds for the first time the correlation between M bacteria and skin phenotype, which is positively correlated with age, and is related to some skin aging phenotypes, such as with the increase of the level of M bacteria, the skin oil decreases, the moisture content decreases, and the luster decreases. It is associated with some typical features of acne, such as increased M bacteria, decreased oil, decreased porphyrins (mostly metabolites of C bacteria, which can be pro-inflammatory), and decreased pore area .
- the present invention finds for the first time that by increasing the relative level (eg content) of P. acnes, M-type skin can be adjusted to C-type skin, which can be used for skin anti-aging.
- the present invention finds for the first time that by increasing the relative level (such as content) of Moraxella oslo, the C-type skin can be adjusted to the M-type skin, which is used for the treatment of acne.
- the present invention finds for the first time that the correlation analysis between single bacteria and skin phenotypes is carried out to explore whether skin microorganisms may cause changes in the skin phenotype of the host, and to provide new insights and new perspectives for the study of the interaction between microorganisms and the host.
- the present invention finds for the first time that the bacterial supernatant is used to treat the host epidermal cells to explore the interaction relationship between the bacteria and the host at the molecular level, and is not limited to correlation research.
- the Shanghai resident population was recruited as volunteers for this study. All volunteers participating in this study will be examined by a dermatologist at Shanghai Dermatology Hospital to rule out skin lesions such as dermatitis, eczema, acne, psoriasis, infection, etc. Skin disease, while excluding volunteers treated with systemic or topical antibiotics within the past 6 months. Finally, 294 healthy subjects aged 20-65 were included, including 46 males (M) and 248 females (F) (Table 1).
- the sampling site was maintained at an indoor temperature of 20 degrees Celsius and a humidity of 50%.
- the experimenter used a special sterile swab dipped in 0.15M NaCl and 0.1% Tween20 solution to repeatedly wipe the subject's forehead (Fh), cheeks (Ch) and paranasal (Ns) three parts about 4cm2 area, back and forth 20 times . Then, the swab was broken, placed in a 1.5ml sterile EP tube, and frozen at -80°C until the skin microorganism genomic DNA was extracted.
- the schematic diagram of the sampling part is shown in Figure 1.
- the samples were amplified by the whole genome amplification method, followed by metagenomic sequencing, and finally the sequencing data of 822 facial skin microbial samples were obtained.
- the relative abundance of each gene was calculated by SOAP2 (version 2.21), and then the sum of the relative abundances of genes from the same strain was calculated according to the alignment result of each gene, which represented the relative abundance of the strain.
- the species level and sebum content, stratum corneum water content, transepidermal water loss rate, skin pH value, pigmentation, Porphyrin, skin color, pores and other phenotypes were subjected to correlation analysis (Spearman Rank method) to evaluate the correlation between strain levels and phenotypes; FDR test was performed on the P value of the correlation analysis results, and the corrected P value ⁇ 0.05 indicated The difference is statistically significant.
- Correlation heatmaps were drawn using the R package pheatmap (version 1.0.12) as the results. Blue, negative correlation; red: positive correlation; significant level of Spearman correlation: *, p ⁇ 0.05; **, p ⁇ 0.01; ***, p ⁇ 0.001.
- MMP Matrix metalloproteinase
- the confirmed bacteria are cultured in liquid, and the pure medium without bacteria inoculation is set as the control group;
- HaCaT cells Culture human keratinocytes 1 ⁇ 10 6 .
- the bacterial liquid supernatant treatment group (experimental group) and the pure medium control group were set, and each group was repeated three times. Gently shake the culture plate to distribute the cells evenly, and place it into a 37°C, 5% CO 2 cell incubator for culture.
- Table 3 is three kinds of bacteria used in the present invention.
- RNA concentration of each sample is adjusted to 200ng/ ⁇ L.
- ii Take a total of 1 ⁇ g of total RNA for reverse transcription reaction, and store the remaining RNA at -80°C;
- QuantiFast SYBR Green PCR Kit of QIAGEN company was used for real-time quantitative PCR (Real-time PCR) to detect the relative expression level of the gene.
- Example 1 Composition of the facial skin microbiome of the Han population
- Example 2 Population typing analysis based on skin microbiome
- the skin microbiome like the gut microbiome, is affected by a variety of factors, and there are significant individual differences.
- the present invention draws on the method of enterotype to classify the population based on skin microbes and explore the driving factors of the type, so as to find the potential rules behind the skin microbiome, and provide a new classification standard for clinical diagnosis.
- the present invention screened subjects with no missing skin microbiome data in three sites, a total of 247 subjects.
- Skin type identification was performed on these 247 subjects based on skin microbiome data.
- the samples from the three parts were clustered using the PAM method, and the CH index was used to determine the optimal number of clusters. Please refer to Figure 3, the results of the CH index show that when the number of clusters is 2, the CH index has the highest score, so the optimal number of clusters in the three parts is 2.
- the present invention performs genotyping analysis on the samples, which are divided into two categories, and respectively use the JSD distance and the Bray-Curtis distance to perform PCoA analysis on the genotyping results of the samples in the three parts.
- Figures 4A-L The results show that the sample typing results of the three parts can be effectively divided into two categories, and the microorganisms that contribute the most to the classification are Propionibacterium acnes and Moraxella oslo, namely a The class enriches P. acnes and the other class enriches Moraxella oslo.
- the two cutotypes we named the two cutotypes as C-Cutotype and M-Cutotype, respectively.
- the present invention analyzes the differential flora of C-Cutotype and M-Cutotype based on the skin microbiome data of the forehead.
- the colors represent relative levels (eg, relative abundance) of microorganisms, with one sample per column and one microorganism per row.
- the results of the differential analysis showed that some microbes prefer a certain skin type, possibly due to the interaction between the flora. For example, P. greedy, P. granulosum, staphylococcus, P. acnes and staphylococcus phage were enriched in C-Cutotype.
- Moraxella bovoculi and Psychrobacter sp. were enriched.
- correlation analysis is performed based on the relative levels of the differential flora, and is displayed in the form of a network diagram.
- the results show that there is a strong positive correlation between microorganisms enriched in the same skin type, while a strong negative correlation exists between microorganisms enriched between different skin types.
- the results of this analysis indicate that microorganisms enriched in the same skin type may occupy different ecological niches, form a stable ecological network with each other, and build a strong microbial community to resist other microorganisms including opportunistic and New colonization of potentially pathogenic microorganisms.
- Type C Hybrid M type cheek ⁇ 0.75 0.75 ⁇ M/C ⁇ 1.68 ⁇ 1.68 forehead ⁇ 1.24 1.24 ⁇ M/C ⁇ 2.18 ⁇ 2.18 Nose ⁇ 0.34 0.34 ⁇ M/C ⁇ 0.55 ⁇ 0.55
- the skin classification sampling principle in clinical application the facial skin parts that need to be improved, and then refer to the above data classification.
- C bacteria the full name of C bacteria is Propionibacterium acnes, and its level (eg abundance) is closely related to skin acne.
- M bacteria There are very few related reports on M bacteria. The present study finds for the first time that M bacteria are correlated with skin phenotypes, are positively correlated with age, and are associated with some skin aging phenotypes.
- the inventors conducted experiments on changes in skin texture and M/C of subjects, and obtained the results in Table 2, which showed that the M/C ratio was related to skin texture.
- As the level of M bacteria increased skin oil decreased, moisture content decreased, gloss decreased, and yellow value (skin dullness) increased; associated with some typical features of acne, such as increased M bacteria, decreased oil, porphyrin Morphine (mostly C bacteria metabolites, which can promote inflammation) decreased, and the pore area decreased.
- Table 7 lists the correlation between related phenotypes and M/C value, and all phenotypes are significantly correlated (p ⁇ 0.05).
- this system is known to be responsible for carbohydrate transport and phosphorylation and is associated with the ability to metabolize glucose, maltose, lactose, fructose and cellobiose, possibly reflecting C-Cutotype's dependence on carbohydrates as a nutrient source.
- Moraxella oslo found that the microbe was unable to utilize any carbohydrates and relied on fatty acids and alcohols as carbon sources. This further suggests that the two skin types may constitute two communities with different nutritional requirements.
- the skin microenvironment is the growth environment of skin microorganisms, it determines the nutrients available to the microorganisms. Therefore, to explore whether the skin phenotype is the driving factor for the different skin types, we further analyzed the phenotypic differences between the two skin types. Referring to Figure 7, it was found that the two skin types had significant differences in stratum corneum moisture, oil, and skin color. In contrast, C-Cutotype has higher oil and moisture content, while M-Cutotype has drier skin. Since oil is the main source of nutrients for microbes, this result further suggests that differences in our nutritional requirements are the driving factors for different skin types.
- the skin phenotypic characteristics of M-Cutotype were similar to those of the elderly, therefore, we compared whether there were differences in age between the two skin types. Please refer to Figure 8.
- the age of the M-Cutotype group was significantly larger than that of the C-Cutotype group, but further analysis found that both C-Cutotype and M-Cutotype existed in different age groups, that is, C-Cutotype in the elderly , M-Cutotype is present in young adults. Therefore, we guess that age is not the real determinant, and nutritional needs are the direct determinant.
- the difference in age may be due to changes in host physiology during aging that affect the skin phenotype, resulting in an older M-Cutotype.
- Example 5 Potential targets for skin aging by M bacteria
- alkylphenol ethoxylates have estrogen-like activities, and it has been proved that these compounds can mimic the effect of estradiol in vivo and in vitro, and are called environmental estrogens. Therefore, skin microbes have the potential to interfere with the production of estradiol, which is essential for preventing skin aging (see Figure 10).
- RNA-Seq Signal pathway enrichment analysis of differentially expressed genes by RNA-Seq suggested that Moraxella oslo could affect skin cells through signaling pathways, mainly including regulation of collagen synthesis and decomposition. Please refer to Figure 12.
- Moraxella oslo was known to be associated with age and skin aging phenotypes.
- a single skin surface compound was used to incubate Moraxella oslo, and the number of viable bacteria was examined to reflect the microbial utilization of different skin surface compounds and the toxicity of specific compounds to Moraxella oslo.
- the growth of Moraxella oslo can be regulated, so as to achieve the purpose of delaying aging.
- CCK-8 and Dye mix A were used to explore the effects of 32 skin surface compounds on the growth of Moraxella oslo.
- the compounds are: L-lysine, L-glutamine, L-histidine, L-arginine, taurocholic acid, creatinine, D-glucose, L-lactic acid, glycerol, 2-carboxybenzaldehyde , urea, SDS, L-threonine, L-tryptophan, glycine, L-methionine, L-serine, L-glutamic acid, L-phenylalanine, L-cystine, L-tyrosine Acid, L-Leucine, L-Isoleucine
- L-ornithine hydrochloride L-citrulline, L-proline, L-valine, L-alanine, D-aspartic acid, trans-4-hydroxy-L- Proline, uric acid, taurine.
- L-glutamine, L-histidine, L-serine, and L-proline significantly promoted the growth of Moraxella oslo, while SDS had a significant inhibitory effect.
- the present invention proves that skin types exist widely and are not affected by skin location, race, health status, and the like.
- a skin condition typing system the system includes a feature receiving module, a calculation processing module and a result output module, each module is connected by wire or wireless, and the typing steps are as follows:
- the skin sample characteristic data is the respective levels of Moraxella oslo and P. acnes.
- the collection site is the same as that described in Embodiment 1, and the detection method is as described in the detection method.
- the processing module receives the skin sample characteristic data from the characteristic receiving module, calculates the respective ratios of the quantified Moraxella oslo and P. acnes or the relative ratios between each other, and based on the obtained respective ratios or the relative proportions of each other, compared with the standard value of skin type or characteristic characterization, so as to obtain the judgment result of skin type and/or skin condition
- a result output module can be any terminal, such as a display, a printer, a tablet computer (PAD), a smart phone, etc., for receiving and outputting the judgment result.
- the system includes a storage, wherein threshold information of standard values is stored in the storage.
- the standard values corresponding to the skin type and/or skin state are:
- Skin type is C (or type I): when the ratio (M/C) of the level (eg content) (M) of the Moraxella oslo to the level (eg content) (C) of the P. acnes When the following conditions are met: M/C ⁇ 1.3, preferably, M/C ⁇ 0.8, more preferably M/C ⁇ 0.4. Skin state of this phenotype: oily, higher water content, good skin elasticity.
- the skin type is M type (type III): when the ratio of the level (eg content) (M) of the Moraxella oslo to the level (eg content) (C) of the P. acnes in the sample ( M/C) meets the following conditions: M/C ⁇ 0.5, preferably, M/C ⁇ 1.8, more preferably, M/C ⁇ 2.2.
- M/C ⁇ 0.5, preferably, M/C ⁇ 1.8, more preferably, M/C ⁇ 2.2 The skin condition of this phenotype: poor oil and water content, poor skin elasticity, and high degree of skin aging.
- the skin type is mixed (or type II): when the ratio (M/C) of the level (eg content) (M) of the Moraxella oslo to the level (eg content) (C) of the P. acnes When the following conditions are met: 0.3 ⁇ M/C ⁇ 2.5, preferably, 0.3 ⁇ M/C ⁇ 2.3, more preferably, 0.8 ⁇ M/C ⁇ 1.8.
- the skin state of this phenotype is between C and M types.
- MMPs matrix metalloproteinases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Cosmetics (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
C型Type C | 混合型Hybrid | M型M type | |
面颊cheek | ≤0.75≤0.75 | 0.75<M/C<1.680.75<M/C<1.68 | ≥1.68≥1.68 |
额头forehead | ≤1.24≤1.24 | 1.24<M/C<2.181.24<M/C<2.18 | ≥2.18≥2.18 |
鼻翼Nose | ≤0.34≤0.34 | 0.34<M/C<0.550.34<M/C<0.55 | ≥0.55≥0.55 |
位置Location | 变量1variable 1 | 变量2variable 2 | 相关系数Correlation coefficient | P值P value |
Fh额头Fh forehead | 卟啉Porphyrin | M/C ratioM/C ratio | -0.4788-0.4788 | 2.30E-162.30E-16 |
油脂grease | M/C ratioM/C ratio | -0.2592-0.2592 | 2.24E-052.24E-05 |
含水量water content | M/C ratioM/C ratio | -0.1782-0.1782 | 3.87E-033.87E-03 | |
光泽度Gloss | M/C ratioM/C ratio | -0.1585-0.1585 | 1.03E-021.03E-02 | |
毛孔面积Pore area | M/C ratioM/C ratio | -0.1405-0.1405 | 2.32E-022.32E-02 | |
Ck面颊Ck cheeks | 卟啉Porphyrin | M/C ratioM/C ratio | -0.4103-0.4103 | 1.65E-121.65E-12 |
含水量water content | M/C ratioM/C ratio | -0.2876-0.2876 | 1.35E-061.35E-06 | |
油脂grease | M/C ratioM/C ratio | -0.2217-0.2217 | 2.22E-042.22E-04 | |
Ns鼻旁Ns beside the nose | 卟啉Porphyrin | M/C ratioM/C ratio | -0.3722-0.3722 | 1.35E-101.35E-10 |
皮肤黄值skin yellowness | M/C ratioM/C ratio | 0.19930.1993 | 8.16E-048.16E-04 | |
毛孔大小Pore size | M/C ratioM/C ratio | -0.1383-0.1383 | 2.09E-022.09E-02 | |
毛孔面积Pore area | M/C ratioM/C ratio | -0.1320-0.1320 | 2.75E-022.75E-02 | |
油脂grease | M/C ratioM/C ratio | 鼻旁未测Nasal not tested | ||
含水量water content | M/C ratioM/C ratio | 鼻旁未测Nasal not tested |
Claims (13)
- 一种奥斯陆莫拉菌或其检测试剂的用途,其特征在于,用于(a)皮肤分型;和/或(b)判断或表征皮肤状态;或用于制备一试剂或试剂盒,所述试剂或试剂盒用于(a)皮肤分型;和/或(b)判断或表征皮肤状态。A use of Moraxella oslo or a detection reagent thereof, characterized in that, for (a) skin typing; and/or (b) judging or characterizing skin condition; or for preparing a reagent or kit, the The reagents or kits are used to (a) type skin; and/or (b) determine or characterize skin conditions.
- 如权利要求1所述的用途,其特征在于,所述皮肤状态包括:皮肤年龄、皮肤含水量、皮肤弹性、皮肤颜色、皮肤衰老程度。The use of claim 1, wherein the skin condition comprises: skin age, skin moisture content, skin elasticity, skin color, and skin aging degree.
- 一种标志物组合,其特征在于,所述标志物组合包括奥斯陆莫拉菌和痤疮丙酸杆菌。A marker combination, characterized in that the marker combination comprises Moraxella oslo and Propionibacterium acnes.
- 如权利要求3所述的标志物组合,其特征在于,所述标志物组合还包含(a)牛眼莫拉氏菌(Moraxella bovoculi)和/或冷杆菌属(Psychrobacter sp.);和/或(b)贪婪丙酸杆菌(Propionibacterium avidum)、颗粒丙酸杆菌(Propionibacterium granulosum)、葡萄球菌属(Staphylococcus)、痤疮丙酸噬菌体和/或葡萄球菌噬菌体。The marker combination of claim 3, wherein the marker combination further comprises (a) Moraxella bovoculi and/or Psychrobacter sp.; and/or (b) Propionibacterium avidum, Propionibacterium granulosum, Staphylococcus, Propionibacterium acnes and/or Staphylococcus phage.
- 一种皮肤分型或判断皮肤状态的方法,其特征在于,所述方法包括:A method for skin typing or judging skin state, characterized in that the method comprises:(1)提供一来源于待测对象皮肤的样品,对样品标志物组合中各标志物的水平进行检测,所述组合包括以下标志物:奥斯陆莫拉菌和痤疮丙酸杆菌,分别获得奥斯陆莫拉菌的水平(M)和痤疮丙酸杆菌的水平(C);(1) Provide a sample derived from the skin of the subject to be tested, and detect the level of each marker in the sample marker combination, where the combination includes the following markers: Moraxella oslo and Propionibacterium acnes, obtained respectively The level of Lageria (M) and the level of P. acnes (C);(2)基于奥斯陆莫拉菌的水平(如含量)(M),或将所述样品中的奥斯陆莫拉菌的水平(M)与痤疮丙酸杆菌的水平(C)进行比较,从而对待测对象的皮肤进行分型、和/或判断皮肤状态。(2) based on the level (such as content) (M) of Moraxella oslo, or by comparing the level (M) of Moraxella oslo with the level (C) of P. acnes in the sample, so as to be tested. The subject's skin is typed, and/or the skin condition is judged.
- 如权利要求5所述的方法,其特征在于,步骤(2)中,根据奥斯陆莫拉菌的水平(M)与痤疮丙酸杆菌的水平(C)的相对值(比如M/C)对皮肤进行分型,或判断样本的皮肤状态。The method according to claim 5, wherein in step (2), according to the relative value (such as M/C) of the level (M) of Moraxella oslo and the level (C) of Propionibacterium acnes (such as M/C) Type, or judge the skin condition of the sample.
- 一种皮肤分型和/或检测皮肤状态的试剂组合,其特征在于,所述试剂组合包括用于检测权利要求3所述的组合中各个标志物的试剂。A reagent combination for skin typing and/or skin condition detection, characterized in that, the reagent combination includes a reagent for detecting each marker in the combination according to claim 3.
- 一种试剂盒,其特征在于,所述的试剂盒包括权利要求7所述的试剂组合。A kit, characterized in that the kit comprises the reagent combination of claim 7 .
- 一种对待测对象的皮肤进行分型和/或判断待测对象的皮肤状态的系统,其特征在于,所述系统包括:A system for classifying the skin of an object to be tested and/or judging the state of the skin of the object to be tested, wherein the system comprises:(a)特征接收模块,所述特征接收模块用于接收皮肤样本特征数据;所述的特征数据包括:皮肤样本中的奥斯陆莫拉菌(M)和痤疮丙酸杆菌(C)各自的定量信息;(a) a feature receiving module, the feature receiving module is used for receiving skin sample feature data; the feature data includes: the quantitative information of each of Moraxella oslo (M) and P. acnes (C) in the skin sample ;(b)计算处理模块,用于计算来自所述特征接收模块的特征数据,从而获得各个特征各自的比例或各个特征之间的比例关系;并且基于所获得的各自的比例或各个特征之间的比例关系,与皮肤分型或特征表征的标准值进行比较,从而得出皮肤分型和/或皮肤状态的判断结果;和(b) a calculation processing module for calculating the feature data from the feature receiving module, so as to obtain the respective proportions of the respective features or the proportional relationship between the respective features; and based on the obtained respective proportions or the relationship between the respective features A proportional relationship, compared with a standard value for skin type or characterization, resulting in a judgment of skin type and/or skin condition; and(c)结果输出模块,所述输出模块用于接收并输出判断结果。(c) a result output module, the output module is used for receiving and outputting the judgment result.
- 如权利要求9所述的系统,其特征在于,所述定量信息的获取方法包括:测序、PCR、蛋白定量检测。The system of claim 9, wherein the method for obtaining the quantitative information comprises: sequencing, PCR, and quantitative protein detection.
- 一种筛选改善皮肤状态物质或成分的方法,其特征在于,包括:A method for screening skin condition-improving substances or ingredients, comprising:(a)提供一筛选菌,所述筛选菌是奥斯陆莫拉菌(M)、痤疮丙酸杆菌(C)、或包含奥斯陆莫拉菌和/或痤疮丙酸杆菌的筛选菌;(a) providing a screening bacteria, the screening bacteria is Moraxella oslo (M), P. acnes (C), or screening bacteria comprising Moraxella oslo and/or P. acnes;(b)将待筛选的物质或成分与所述筛选菌进行共培养,并检测奥斯陆莫拉菌或痤疮丙酸杆菌各自的水平;或奥斯陆莫拉菌与痤疮丙酸杆菌之间的相对水平(M/C);(b) co-culturing the substance or component to be screened with the screening bacteria, and detecting the respective levels of Moraxella oslo or P. acnes; or the relative level between Moraxella oslo and P. acnes ( M/C);(c)根据(b)培养后奥斯陆莫拉菌或痤疮丙酸杆菌各自的水平;或奥斯陆莫拉菌与痤疮丙酸杆菌之间的相对水平(M/C),从而判断所述待筛选的物质或成分为改善皮肤状态物质或成分。(c) according to (b) the respective levels of Moraxella oslo or P. acnes after culture; or the relative level (M/C) between Moraxella oslo and P. acnes, thereby judging the to-be-screened The substance or ingredient is a skin condition-improving substance or ingredient.
- 如权利要求11所述的方法,其特征在于,步骤(c)中奥斯陆莫拉菌的水平提高,或奥斯陆莫拉菌与痤疮丙酸杆菌之间的相对水平(M/C)提高,或痤疮丙酸杆菌的水平降低,或痤疮丙酸杆菌与奥斯陆莫拉菌之间的相对水平(C/M)降低时,所述待筛选的物质或成分为用于治疗痤疮的物质;和/或步骤(c)中奥斯陆莫拉菌的水平下降,或奥斯陆莫拉菌与痤疮丙酸杆菌之间的相对水平(M/C)下降,或痤疮丙酸杆菌的水平提高,或痤疮丙酸杆菌与奥斯陆莫拉菌之间的相对水平(C/M)提高,所述待筛选的物质或成分为皮肤抗衰老物质。The method of claim 11, wherein in step (c), the level of Moraxella oslo is increased, or the relative level (M/C) between Moraxella oslo and P. acnes is increased, or acne When the level of Propionibacterium is decreased, or the relative level (C/M) between Propionibacterium acnes and Moraxella oslo is decreased, the substance or ingredient to be screened is a substance for treating acne; and/or step (c) decreased levels of Moraxella oslo, or decreased relative levels (M/C) between Moraxella oslo and P. acnes, or increased levels of P. acnes, or increased levels of P. acnes and P. acnes The relative level (C/M) of Moraxella was increased, and the substance or ingredient to be screened was a skin anti-aging substance.
- 一种权利要求3所述的标志物组合或权利要求7所述的试剂组合的用途,其特征在于,(a)用于制备一试剂盒,所述试剂盒用于皮肤分型,和/或判断或表征皮肤状态;和/或(b)用于筛选改善皮肤状态的物质或成分。A use of the combination of markers of claim 3 or the combination of reagents of claim 7, wherein (a) is used to prepare a kit for skin typing, and/or Assessing or characterizing skin condition; and/or (b) screening for substances or ingredients that improve skin condition.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237023407A KR20230118928A (en) | 2020-12-08 | 2021-12-06 | Marker combination for skin typing and its application |
JP2023535014A JP2023552837A (en) | 2020-12-08 | 2021-12-06 | Marker combinations and their use for skin classification |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011444009 | 2020-12-08 | ||
CN202011444009.3 | 2020-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022121864A1 true WO2022121864A1 (en) | 2022-06-16 |
Family
ID=81898667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/135870 WO2022121864A1 (en) | 2020-12-08 | 2021-12-06 | Marker combination for skin typing and use thereof |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2023552837A (en) |
KR (1) | KR20230118928A (en) |
CN (1) | CN114622024A (en) |
WO (1) | WO2022121864A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102465182A (en) * | 2010-10-29 | 2012-05-23 | 株式会社爱茉莉太平洋 | Detection kit for skin-active ingredients and method for detecting skin-active ingredients by using the same |
CN103898006A (en) * | 2014-01-28 | 2014-07-02 | 重庆市畜牧科学院 | Goat source moraxella osloensis and specific segment for molecular identification of goat source moraxella osloensis as well as application of specific segment |
CN108690881A (en) * | 2017-03-30 | 2018-10-23 | 欧蒙医学诊断技术有限公司 | Measuring method for diagnosing dermatophytosis |
-
2021
- 2021-12-06 KR KR1020237023407A patent/KR20230118928A/en active Search and Examination
- 2021-12-06 WO PCT/CN2021/135870 patent/WO2022121864A1/en active Application Filing
- 2021-12-06 CN CN202111481392.4A patent/CN114622024A/en active Pending
- 2021-12-06 JP JP2023535014A patent/JP2023552837A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102465182A (en) * | 2010-10-29 | 2012-05-23 | 株式会社爱茉莉太平洋 | Detection kit for skin-active ingredients and method for detecting skin-active ingredients by using the same |
CN103898006A (en) * | 2014-01-28 | 2014-07-02 | 重庆市畜牧科学院 | Goat source moraxella osloensis and specific segment for molecular identification of goat source moraxella osloensis as well as application of specific segment |
CN108690881A (en) * | 2017-03-30 | 2018-10-23 | 欧蒙医学诊断技术有限公司 | Measuring method for diagnosing dermatophytosis |
Non-Patent Citations (2)
Title |
---|
ALKHATIB NIDAL J., YOUNIS MANAF H., ALOBAIDI AHMAD S., SHAATH NEBAL M.: "An unusual osteomyelitis caused by Moraxella osloensis: A case report", INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, ELSEVIER, AMSTERDAM, NL, vol. 41, 1 January 2017 (2017-01-01), AMSTERDAM, NL, pages 146 - 149, XP055941183, ISSN: 2210-2612, DOI: 10.1016/j.ijscr.2017.10.022 * |
LIM JAE YUN, HWANG INGYU, GANZORIG MUNKHTSATSRAL, HUANG SHIR-LY, CHO GYU-SUNG, FRANZ CHARLES M. A. P., LEE KYOUNG: "Complete Genome Sequences of Three Moraxella osloensis Strains Isolated from Human Skin", GENOME ANNOUNCEMENTS, vol. 6, no. 3, 18 January 2018 (2018-01-18), XP055941180, DOI: 10.1128/genomeA.01509-17 * |
Also Published As
Publication number | Publication date |
---|---|
CN114622024A (en) | 2022-06-14 |
KR20230118928A (en) | 2023-08-14 |
JP2023552837A (en) | 2023-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boxberger et al. | Challenges in exploring and manipulating the human skin microbiome | |
Saxena et al. | Comparison of healthy and dandruff scalp microbiome reveals the role of commensals in scalp health | |
Hyde et al. | Metagenomic analysis of nitrate-reducing bacteria in the oral cavity: implications for nitric oxide homeostasis | |
Howard et al. | Aging-associated changes in the adult human skin microbiome and the host factors that affect skin microbiome composition | |
Trappetti et al. | The impact of the competence quorum sensing system on Streptococcus pneumoniae biofilms varies depending on the experimental model | |
Khayyira et al. | Simultaneous profiling and cultivation of the skin microbiome of healthy young adult skin for the development of therapeutic agents | |
CN109589275A (en) | Ectoin is maintaining the purposes in skin microecological balance | |
CN114717128B (en) | Lactobacillus reuteri with effects of improving aging skin and enhancing hair health and application thereof | |
CN111944713B (en) | Pediococcus acidilactici with excellent alcohol stress resistance and application thereof | |
CN114574393A (en) | Lactobacillus delbrueckii SEUNEU-110 and application thereof in skin | |
Marques et al. | Phenotypic characterization of mastitic Prototheca spp. isolates | |
WO2022121864A1 (en) | Marker combination for skin typing and use thereof | |
Patil et al. | Isolation and characterisation of Lactobacillus species from sheep milk | |
Li et al. | Comparative genomics of in vitro and in vivo evolution of probiotics reveals energy restriction not the main evolution driving force in short term | |
KR20230104670A (en) | Novel compositions for the treatment of skin conditions | |
AL-ZAIDI et al. | Molecular determination of the microbial diversity associated with vaginitis and testing their sensitivity to selected antimicrobials | |
Xia et al. | Integration of skin phenome and microbiome reveals the key role of bacteria in human skin aging | |
Hussain et al. | MALDI-TOF vs. VITEK 2 for identification of Aggregatibacter actinomycetemcomitans chest wall abscess | |
Cui et al. | Metagenomic insights into the effects of cosmetics containing complex polysaccharides on the composition of skin microbiota in females | |
Li et al. | The prebiotic effect of triple biotic technology on skin health | |
Diouf et al. | Description of Streptococcus thalassemiae sp. nov., a Bacterium Isolated from Human Blood | |
Wilson | The human microbiota: an historical perspective | |
Ze’evi Ma’or et al. | Topical Application of Synbiotic Bacillus Preparations Positively Affects Skin (Micro) Biology | |
CN110616163B (en) | Enterococcus faecalis capable of reducing concentration of trimethylamine and preparation method and application thereof | |
CN117551590B (en) | Bifidobacterium longum subspecies infantis, microbial agent and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21902569 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023535014 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20237023407 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11202305203Y Country of ref document: SG |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21902569 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16/11/2023) |